Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Profound Medical Corp (PROF)

Profound Medical Corp (PROF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 239,540
  • Shares Outstanding, K 36,294
  • Annual Sales, $ 10,680 K
  • Annual Income, $ -27,820 K
  • EBIT $ -43 M
  • EBITDA $ -42 M
  • 60-Month Beta 0.60
  • Price/Sales 13.40
  • Price/Cash Flow N/A
  • Price/Book 5.85

Options Overview Details

View History
  • Implied Volatility 170.62% (-254.56%)
  • Historical Volatility 65.87%
  • IV Percentile 87%
  • IV Rank 33.50%
  • IV High 425.18% on 02/10/26
  • IV Low 42.39% on 05/19/25
  • Expected Move (DTE 5) 0.06 (0.90%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 19
  • Volume Avg (30-Day) 60
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 1,293
  • Open Int (30-Day) 1,627
  • Expected Range 6.54 to 6.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.27
  • Number of Estimates 2
  • High Estimate -0.24
  • Low Estimate -0.30
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -35.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.00 +10.00%
on 02/12/26
8.60 -23.26%
on 01/16/26
-1.78 (-21.24%)
since 01/13/26
3-Month
5.74 +14.98%
on 11/20/25
8.95 -26.26%
on 01/13/26
+0.25 (+3.94%)
since 11/13/25
52-Week
3.76 +75.53%
on 09/10/25
8.95 -26.26%
on 01/13/26
+0.31 (+4.93%)
since 02/13/25

Most Recent Stories

More News
Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative...

PRN.TO : 8.90 (+4.71%)
PROF : 6.60 (+5.94%)
Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures,...

PRN.TO : 8.90 (+4.71%)
PROF : 6.60 (+5.94%)
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health

TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

PRN.TO : 8.90 (+4.71%)
PROF : 6.60 (+5.94%)
Profound Medical Announces Upcoming Investor Events

TORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered,...

PRN.TO : 8.90 (+4.71%)
PROF : 6.60 (+5.94%)
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®

Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World Report...

PRN.TO : 8.90 (+4.71%)
PROF : 6.60 (+5.94%)
Profound Surpasses 2025 TULSA-PRO® Installed Base Goal

TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered,...

PRN.TO : 8.90 (+4.71%)
PROF : 6.60 (+5.94%)
Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case

TORONTO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered,...

PRN.TO : 8.90 (+4.71%)
PROF : 6.60 (+5.94%)
Profound Medical Corp. Announces Closing of Private Placement

TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced...

PRN.TO : 8.90 (+4.71%)
PROF : 6.60 (+5.94%)
Profound Medical Corp. Announces Upsize of Private Placement

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement...

PRN.TO : 8.90 (+4.71%)
PROF : 6.60 (+5.94%)
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th

TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the closing of its previously announced registered direct...

PRN.TO : 8.90 (+4.71%)
PROF : 6.60 (+5.94%)

Business Summary

Profound Medical Corp. is a medical technology company. It is focused on a therapeutics platform which provides the precision of real-time Magnetic Resonance Imaging technology for the incision-free ablation of diseased tissue. The company principally commercialized the TULSA-PRO(R) and Sonalleve(R)...

See More

Key Turning Points

3rd Resistance Point 7.39
2nd Resistance Point 7.09
1st Resistance Point 6.84
Last Price 6.60
1st Support Level 6.29
2nd Support Level 5.99
3rd Support Level 5.74

See More

52-Week High 8.95
Fibonacci 61.8% 6.97
Last Price 6.60
Fibonacci 50% 6.36
Fibonacci 38.2% 5.74
52-Week Low 3.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar